Quick Answer
NextCure, Inc. reported Cash and Equivalents of $25.98 million for fiscal year 2025.
NextCure, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $25.98M | -6.3% |
| 2024 | $27.73M | +111.9% |
| 2023 | $13.08M | -50.9% |
| 2022 | $26.63M | +115.9% |
| 2021 | $12.34M | -62.4% |
| 2020 | $32.77M | -3.9% |
| 2019 | $34.09M | -74.8% |
| 2018 | $135.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.32M | -73.6% | +49.7% |
| June 30, 2025 | $4.89M | -76.5% | -77.6% |
| March 31, 2025 | $21.83M | +18.9% | -21.3% |
| December 31, 2024 | $27.73M | +111.9% | +0.1% |
| September 30, 2024 | $27.70M | +41.9% | +32.9% |
| June 30, 2024 | $20.85M | -5.3% | +13.6% |
| March 31, 2024 | $18.36M | -38.8% | +40.3% |
| December 31, 2023 | $13.08M | -50.9% | -33.0% |
- NextCure, Inc. showed a decrease of -6.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, NextCure, Inc.’s cash and equivalents has declined by 80.8% (from $135.17 million to $25.98 million).
- The most recent figure is from NextCure, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: